MX2017005884A - Metodos para el tratamiento de la erc, utilizando predictores de la retencion de liquidos. - Google Patents

Metodos para el tratamiento de la erc, utilizando predictores de la retencion de liquidos.

Info

Publication number
MX2017005884A
MX2017005884A MX2017005884A MX2017005884A MX2017005884A MX 2017005884 A MX2017005884 A MX 2017005884A MX 2017005884 A MX2017005884 A MX 2017005884A MX 2017005884 A MX2017005884 A MX 2017005884A MX 2017005884 A MX2017005884 A MX 2017005884A
Authority
MX
Mexico
Prior art keywords
methods
predictors
fluid retention
treating ckd
treating
Prior art date
Application number
MX2017005884A
Other languages
English (en)
Inventor
Andress Dennis
K Kohan Donald
Coll Blai
J Lambers Heerspink Hiddo
DE ZEEUM Dick
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2017005884A publication Critical patent/MX2017005884A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se refiere a métodos para el tratamiento de la enfermedad renal crónica y la nefropatía diabética, utilizando predictores de la retención de líquidos para minimizar el riesgo de eventos adversos. Los métodos descritos son particularmente útiles en tratamientos que involucran el uso de antagonistas del receptor de endotelina, y más particularmente, atrasentán y sales farmacéuticamente aceptables del mismo.
MX2017005884A 2014-11-07 2015-11-06 Metodos para el tratamiento de la erc, utilizando predictores de la retencion de liquidos. MX2017005884A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462077108P 2014-11-07 2014-11-07
PCT/US2015/059456 WO2016073846A1 (en) 2014-11-07 2015-11-06 Methods of treating ckd using predictors of fluid retention

Publications (1)

Publication Number Publication Date
MX2017005884A true MX2017005884A (es) 2017-06-26

Family

ID=55909856

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005884A MX2017005884A (es) 2014-11-07 2015-11-06 Metodos para el tratamiento de la erc, utilizando predictores de la retencion de liquidos.

Country Status (9)

Country Link
US (1) US20160128980A1 (es)
EP (1) EP3215138A4 (es)
JP (1) JP2017534634A (es)
CN (1) CN107106522A (es)
AU (1) AU2015342929A1 (es)
BR (1) BR112017009668A2 (es)
CA (1) CA2966756A1 (es)
MX (1) MX2017005884A (es)
WO (1) WO2016073846A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3197344B1 (en) 2014-09-23 2023-05-03 Icahn School of Medicine at Mount Sinai Systems and methods for treating a psychiatric disorder
MY199557A (en) 2017-02-27 2023-11-07 Idorsia Pharmaceuticals Ltd Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
US12144811B2 (en) 2017-11-30 2024-11-19 Idorsia Pharmaceuticals Ltd Combination of a 4-pyrimidinesulfamide derivative with an SGLT-2 inhibitor for the treatment of endothelin related diseases
MX2022007471A (es) * 2019-12-17 2022-08-17 Chinook Therapeutics Inc Metodos de tratamiento de la nefropatia por iga con atrasentan.
IL317076A (en) 2022-05-22 2025-01-01 Idorsia Pharmaceuticals Ltd Aprociten for the treatment of hypertension
CN118262911B (zh) * 2024-03-12 2024-08-20 广东省人民医院 一种糖尿病患者dme风险评估模型及早期筛查系统

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2190433A2 (en) * 2007-08-22 2010-06-02 Gilead Colorado, Inc. Therapy for complications of diabetes
US20140073575A1 (en) * 2011-04-15 2014-03-13 Universitaet Zuerich Prorektorat Mnw Collagen hydroxylases
WO2014138738A1 (en) * 2013-03-08 2014-09-12 Abbive Inc. Methods of treating acute kidney injury

Also Published As

Publication number Publication date
AU2015342929A1 (en) 2017-05-25
CA2966756A1 (en) 2016-05-12
US20160128980A1 (en) 2016-05-12
EP3215138A4 (en) 2018-11-21
EP3215138A1 (en) 2017-09-13
JP2017534634A (ja) 2017-11-24
BR112017009668A2 (pt) 2017-12-26
CN107106522A (zh) 2017-08-29
WO2016073846A1 (en) 2016-05-12

Similar Documents

Publication Publication Date Title
MX2017005884A (es) Metodos para el tratamiento de la erc, utilizando predictores de la retencion de liquidos.
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
LT3472153T (lt) Pirimidin-2-ilamino-1h-pirazolai kaip lrrk2 inhibitoriai, skirti naudoti neurodegeneracinių sutrikimų gydyme
MX2017015226A (es) Compuestos alqueno tetrasustituidos y su uso.
LT3253865T (lt) Metodai, skirti sustiprinti terapinių imuninių ląstelių veiksmingumą
EA201791884A1 (ru) Химерные антигенные рецепторы против dll3 и способы применения
EA201691683A1 (ru) Антитела против dll3 и конъюгаты антитело-лекарственное средство для применения при меланоме
PH12015502275A1 (en) Therapuetic uses of empagliflozin
JO3553B1 (ar) تعديل المناعة ضد الورم
TR201902516T4 (tr) Glukagon-glp-1-gıp üçlü agonist bileşikleri.
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
MX2020010004A (es) Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos.
BR112017005598A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
EA201691314A1 (ru) Терапевтические способы и композиции
PH12016501051A1 (en) Methods of treasting and preventing alloantibody driven chronic graft versus host disease
GB201409936D0 (en) System, method and program for securely managing financial transactions
EA201692534A1 (ru) Способы лечения гипотонии
PL3600415T3 (pl) Przeciwciało przeciwko receptorowi aktywiny typu II do stosowania w leczeniu niewydolności serca
GB201710646D0 (en) Methods for development and use of minimally polarized function cell micro-aggregate units in tissue applications using LGR4, LGR5 and LGR6
MX2017009281A (es) Antihistamina para usar en el tratamiento de cancer de seno.
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
MX2017016533A (es) Metodo para tratar glomeruloesclerosis focal y segmentaria primaria.
NZ727147A (en) Combination therapy comprising olaratumab and doxorubicin
EA201301080A1 (ru) Применение солей 3-карбокси-n-этил-n,n-диметилпропан-1-аммония при лечении сердечно-сосудистого заболевания
MA40574A (fr) Traitement de maladies fibrotiques